Tori Allen says she’s thrilled to have lost 80 pounds since she went on Wegovy, one of the GLP-1 drugs that more and more ...

A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less ...

Millions of Brits are now eligible for the appetite-suppressing jabs which can come with unpleasant side effects - but NHS rationing means only a tiny fraction will be prescribed them ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, ...

Its weight-loss drug policy would fall to Trump's pick for health secretary, Robert F Kennedy Jr, and Mehmet Oz, Trump's ...

News research shows GLP-1 medications may help treat a wide range of conditions, from addiction and dementia to heart disease ...

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide ...

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...